Cargando…

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Detalles Bibliográficos
Autores principales:	Franco, Jorge, Balaji, Uthra, Freinkman, Elizaveta, Witkiewicz, Agnieszka K., Knudsen, Erik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540600/ https://www.ncbi.nlm.nih.gov/pubmed/32640213 http://dx.doi.org/10.1016/j.celrep.2020.107793

Ejemplares similares

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential
por: Knudsen, Erik S., et al.
Publicado: (2016)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
por: Franco, Jorge, et al.
Publicado: (2014)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
por: Kumarasamy, Vishnu, et al.
Publicado: (2019)

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
por: Knudsen, Erik S, et al.
Publicado: (2018)

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2014)

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
por: Knudsen, Erik S., et al.
Publicado: (2019)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2021)

Metabolic Reprogramming and Vulnerabilities in Cancer
por: Lyssiotis, Costas A., et al.
Publicado: (2019)

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints
por: Cannon, Alexa C., et al.
Publicado: (2023)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

p18 inhibits reprogramming through inactivation of Cdk4/6
por: Zhu, Shaohua, et al.
Publicado: (2016)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer
por: Hsu, Ming-Chuan, et al.
Publicado: (2019)

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
por: Brown, Nicholas R., et al.
Publicado: (2015)

The metabolic reprogramming and vulnerability of SF3B1 mutations
por: Dalton, W. Brian
Publicado: (2020)

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
por: Weinberg, Benjamin A., et al.
Publicado: (2020)

Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway
por: Zhang, Yi, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway
por: Santiappillai, Nancy T., et al.
Publicado: (2021)

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020)

Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis
por: Mackenzie, Jared S., et al.
Publicado: (2020)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations
por: Grant, Adam D., et al.
Publicado: (2019)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor
por: Sawant, Mithila, et al.
Publicado: (2023)

The biological role of metabolic reprogramming in pancreatic cancer
por: Suzuki, Tatsunori, et al.
Publicado: (2020)

The role of metabolic reprogramming in pancreatic cancer chemoresistance
por: Liu, Chang, et al.
Publicado: (2023)

Cerina: systematic circRNA functional annotation based on integrative analysis of ceRNA interactions
por: Cardenas, Jacob, et al.
Publicado: (2020)

Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms
por: Balasubramanian, Suganthi, et al.
Publicado: (2005)

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma
por: Frede, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0lf6sgpmji6q9nouo36l0hknog